Try our beta test site
41 studies found for:    "Tardive dyskinesia"
Show Display Options
Rank Status Study
1 Completed Piracetam for Treatment Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: piracetam
2 Completed Treatment of Tardive Dyskinesia With Galantamine
Condition: Tardive Dyskinesia
Intervention: Drug: Galantamine
3 Not yet recruiting Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
Condition: Tardive Dyskinesia
Intervention: Device: Repetitive Transcranial Magnetic Stimulation
4 Unknown  Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Dietary Supplement: Omega-3 fish oil capsules (including DHA);   Dietary Supplement: Placebo
5 Terminated Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: Pyridoxal 5'-Phosphate;   Drug: Placebo
6 Completed Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
Condition: Tardive Dyskinesia
Interventions: Drug: Melatonin;   Drug: Placebo
7 Withdrawn Pyridoxal Kinase Activity in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: Pyridoxine
8 Terminated Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Condition: Neuroleptic-induced Tardive Dyskinesia
Interventions: Drug: Sarizotan;   Other: Placebo
9 Active, not recruiting Reducing Involuntary Movements in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: SD-809
10 Completed Addressing Involuntary Movements in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: SD-809;   Drug: Placebo
11 Completed Aim to Reduce Movements in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: SD-809;   Drug: Placebo
12 Active, not recruiting Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: NBI-98854
13 Completed NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854;   Drug: Placebo
14 Completed A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854;   Drug: Placebo
15 Completed Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: NBI-98854
16 Completed Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia
Condition: Neuroleptic-Induced Tardive Dyskinesia
Interventions: Drug: risperidone;   Drug: olanzapine
17 Completed Tardive Dyskinesia and Cognitive Function
Conditions: Tardive Dyskinesia;   Neurocognitive Function
Interventions: Drug: amisulpride;   Drug: Olanzapine;   Drug: Conventional antipsychotics
18 Completed NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854;   Drug: Placebo
19 Completed NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854;   Drug: Placebo
20 Completed A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
Condition: Drug-induced Tardive Dyskinesia
Interventions: Drug: SNC-102;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.